Press Releases

Press Releases

Date Title  
Sep 03, 2021
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Sept. 03, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that in connection with hiring a new employee, the
Sep 01, 2021
Prothena to Participate in Upcoming September Healthcare Conferences
DUBLIN, Ireland , Sept. 01, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in
Aug 05, 2021
Prothena Reports Second Quarter 2021 Financial Results and Business Highlights
Net cash provided by operating and investing activities was $36.6 million in the second quarter and $2.9 million for the first six months of 2021; quarter-end cash and restricted cash position of $402.5 million (includes $60 million payment from Roche) provides additional funding to continue
Jul 29, 2021
Prothena to Report Second Quarter 2021 Financial Results on August 5th
DUBLIN, Ireland , July 29, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, announced today that it will report its second quarter and first six
Jul 26, 2021
Prothena Presents New Data from Robust Alzheimer’s Portfolio at the Alzheimer’s Association International Conference 2021
Late-breaking PRX012 poster highlights significant ex vivo clearance of both pyroglutamate-modified and -unmodified Aβ plaque from AD brain at concentrations expected to be reached in CNS with subcutaneous administration Poster presentation demonstrates dual Aβ-tau vaccines simultaneously generate
Jul 20, 2021
Prothena to Present Data from Two of its Alzheimer’s Disease Programs at the Alzheimer’s Association International Conference 2021
DUBLIN, Ireland , July 20, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that it will present preclinical data on two of its
Jul 12, 2021
Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena’s ATTR Amyloidosis Programme
Prothena is eligible to receive development and sales milestone payments totalling up to 1.2 billion US dollars , including 100 million dollars in upfront and near-term clinical milestone payments Novo Nordisk will develop the phase 2 ready antibody PRX004 for the rare heart disease ATTR
Jun 24, 2021
Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration
Prothena to receive $80 million from Bristol Myers Squibb for exclusive US license to PRX005; Next option for worldwide rights following completion of Phase 1 PRX005 is an investigational best-in-class anti-tau antibody targeting the microtubule binding region of tau for the treatment of
Jun 10, 2021
Prothena to Participate in JMP Securities Life Sciences Conference on June 16
DUBLIN, Ireland , June 10, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a
May 20, 2021
Prothena Announces Appointment of Sanjiv Patel, MBBS, to its Board of Directors
DUBLIN, Ireland , May 20, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Sanjiv K.